$3,750.00
This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products.
Osteoporosis is a common metabolic bone disease that is characterized by the loss of bone mineral density (BMD). The disease contributes to weakened bone tissue and a propensity for fractures, and is one of the major contributors to orthopedic injuries, especially in women. Although the disease is not restricted to women, and many factors contribute to the cause of osteoporosis, the most significant factor for women is menopause. An increase in this demographic group will play a key role in the continual demand for osteoporosis management products during the forecast period covered by this report.
This report provides analyses of products, markets, and competitors in the United States (U.S.) market for osteoporosis management products. This market, as covered by the scope of this report, includes products that are used to diagnose and treat osteoporosis including bone densitometry systems, bone remodeling biochemical marker tests, and pharmaceutical treatments such as estrogen/hormone therapy (HT) and osteoporosis drugs.
1. OVERVIEW OF OSTEOPOROSIS …………………………………………………….. 1-1
1.1 Incidence, Prevalence, and Cost………………………………………………. 1-2
1.2 Types of Osteoporosis…………………………………………………………….. 1-6
1.3 Risk Factors ………………………………………………………………………….. 1-8
Exhibit 1-1: Osteoporotic Bone and Normal Bone………………………………………… 1-3
Exhibit 1-2: 2012, Osteoporosis-Caused Fracture Incidence, by Site ……………… 1-5
Exhibit 1-3: Osteoporosis or Low Bone Mass in Women Age 50 and Older,
by Race and Ethnicity……………………………………………………………… 1-7
Exhibit 1-4: Types of Osteoporosis…………………………………………………………….. 1-9
Exhibit 1-5: Leading Risk Factors for Osteoporosis…………………………………….. 1-10
2013 Elsevier Business Intelligence i #A331
Women’s Health: Trends and Opportunities in the
U.S. Osteoporosis Management Market Table of Contents
2. BONE DENSITOMETRY PRODUCTS MARKET …………………………………. 2-1
2.1 Bone Densitometry Overview …………………………………………………… 2-1
2.1.1 Dual-Energy X-Ray Absorptiometry ……………………………. 2-3
2.1.2 Single-Energy X-Ray Absorptiometry………………………….. 2-5
2.1.3 Radiographic Absorptiometry …………………………………….. 2-5
2.1.4 Quantitative Computed Tomography…………………………… 2-5
2.1.5 Quantitative Ultrasound…………………………………………….. 2-6
2.1.6 Hospital-Based Densitometry Systems ……………………….. 2-9
2.1.7 Office-Based Densitometry Systems…………………………… 2-9
2.1.8 Software-Based Densitometry Systems ………………………. 2-9
2.2 Densitometry Products ………………………………………………………….. 2-10
2.2.1 BeamMed……………………………………………………………… 2-10
2.2.2 CompuMed……………………………………………………………. 2-10
2.2.3 CooperSurgical/The Cooper Companies……………………. 2-11
2.2.4 Furuno USA/Furuno Electric Company ……………………… 2-12
2.2.5 GE Healthcare/General Electric Company …………………. 2-12
2.2.6 Hologic …………………………………………………………………. 2-12
2.2.7 Lone Oak Medical Technologies ………………………………. 2-13
2.2.8 Sectra…………………………………………………………………… 2-13
2.3 Reimbursement ……………………………………………………………………. 2-23
2.4 Market Analysis ……………………………………………………………………. 2-23
2.5 Competitive Analysis …………………………………………………………….. 2-27
Exhibit 2-1: Comparison of Biochemical Markers and Bone Densitometry
as Tools for Diagnosing and Monitoring Osteoporosis …………………. 2-2
Exhibit 2-2: Imaging Technologies Used to Diagnose Osteoporosis……………….. 2-7
Exhibit 2-3: 2013, Selected Bone Densitometry Systems ……………………………. 2-14
Exhibit 2-4: The Sunlight MiniOmni Bone Sonometer …………………………………. 2-16
Exhibit 2-5: The Norland Family of Dual-Energy X-Ray
Absorptiometry Systems………………………………………………………… 2-17
Exhibit 2-6: The Lunar iDXA Dual-Energy X-Ray Absorptiometry System ……… 2-18
Exhibit 2-7: The Discovery Dual-Energy X-Ray Absorptiometry System………… 2-19
Exhibit 2-8: The OsteoGram Radiographic Absorptiometry System………………. 2-20
Exhibit 2-9: The CM-200 Quantitative Ultrasound Bone
Densitometry System ……………………………………………………………. 2-21
Exhibit 2-10: The Accudxa2 Dual-Energy X-Ray Absorptiometry System………… 2-22
Exhibit 2-11: Hospital-Based Bone Densitometry Systems,
Market Forecast, 2012-2017 ………………………………………………….. 2-25
Exhibit 2-12: Office-Based Bone Densitometry Systems,
Market Forecast, 2012-2017 ………………………………………………….. 2-26
Exhibit 2-13: Total Bone Densitometry Systems,
Market Forecast, 2012-2017 ………………………………………………….. 2-28
Exhibit 2-14: 2012, Bone Densitometry Systems Market,
Share by Supplier…………………………………………………………………. 2-29
3. BONE REMODELING BIOCHEMICAL MARKER TESTS MARKET………. 3-1
3.1 Biochemical Markers Overview ………………………………………………… 3-1
3.1.1 Types of Bone Turnover Markers……………………………….. 3-2
3.1.2 Applications…………………………………………………………….. 3-2
3.2 Biochemical Marker Testing Products ……………………………………….. 3-6
3.2.1 Alere………………………………………………………………………. 3-6
3.2.2 Beckman Coulter……………………………………………………… 3-6
3.2.3 Roche Diagnostics/Roche …………………………………………. 3-6
3.2.4 Immunodiagnostic Systems……………………………………….. 3-7
3.2.5 Orion Diagnostica/Orion Group ………………………………….. 3-7
3.2.6 Quidel…………………………………………………………………….. 3-8
3.3 Reimbursement ……………………………………………………………………… 3-8
3.4 Market Analysis ……………………………………………………………………. 3-13
3.5 Competitive Analysis …………………………………………………………….. 3-14
Exhibit 3-1: The Bone Remodeling Cycle……………………………………………………. 3-3
Exhibit 3-2: Comparison of Selected Bone Remodeling
Biochemical Marker Tests ……………………………………………………….. 3-4
Exhibit 3-3: 2013, Selected Bone Remodeling Biochemical Marker Tests ……….. 3-9
Exhibit 3-4: Bone Remodeling Biochemical Marker Tests,
Market Forecast, 2012-2017 ………………………………………………….. 3-15
Exhibit 3-5: 2012, Bone Remodeling Biochemical Marker Tests Market,
Share by Supplier…………………………………………………………………. 3-16
4. OSTEOPOROSIS PHARMACEUTICAL TREATMENTS MARKET………… 4-1
4.1 Clinical Overview……………………………………………………………………. 4-1
4.1.1 Antiresorptive Drugs…………………………………………………. 4-2
4.1.1.1 Bisphosphonates……………………………………….. 4-2
4.1.1.1.1 Alendronate …………………………… 4-3
4.1.1.1.2 Ibandronate……………………………. 4-5
4.1.1.1.3 Risedronate …………………………… 4-6
4.1.1.1.4 Zoledronate……………………………. 4-7
4.1.1.2 Salmon Calcitonins…………………………………….. 4-8
4.1.1.2.1 Novartis…………………………………. 4-9
4.1.1.2.2 Unigene Laboratories…………….. 4-10
4.1.1.2.3 Emerging Drugs……………………. 4-10
4.1.1.3 Estrogen/Hormone Therapy ………………………. 4-15
4.1.1.4 Receptor Activator of Nuclear Factor
KappaB Ligand Inhibitors ………………………….. 4-17
4.1.1.5 Estrogen Agonists/Antagonists…………………… 4-17
4.1.1.5.1 Emerging Drugs……………………. 4-19
4.1.1.5.1.1 Pfizer ……………….. 4-19
4.1.1.5.1.2 EndoCeutics ……… 4-20
4.1.1.6 Other Emerging Antiresorptives …………………. 4-20
4.1.1.6.1 Cathepsin K Inhibitors……………. 4-20
4.1.1.6.2 Monoclonal Antibodies…………… 4-21
4.1.1.6.2.1 Alethia
Biotherapeutics….. 4-21
4.1.1.6.2.2 Novo Nordisk…….. 4-21
4.1.2 Bone-Forming Drugs ………………………………………………. 4-21
4.1.2.1 Synthetic Parathyroid Hormone………………….. 4-22
4.1.2.1.1 Forteo …………………………………. 4-22
4.1.2.1.2 Pipeline Drugs………………………. 4-23
4.1.2.1.2.1 Radius Health……. 4-24
4.1.2.2 Other Emerging Anabolic Drugs…………………. 4-25
4.1.2.2.1 Serotonin Inhibitors……………….. 4-25
4.1.3 Bone Morphogenetic Proteins ………………………………….. 4-26
4.1.4 Dual-Action Bone Agents ………………………………………… 4-26
4.1.4.1 Strontium Ranelate…………………………………… 4-27
4.1.4.2 Strontium Malonate ………………………………….. 4-28
4.1.5 Gene Therapy ……………………………………………………….. 4-28
4.2 Market Analysis ……………………………………………………………………. 4-29
4.2.1 Estrogen/Hormone Therapy Drugs……………………………. 4-35
4.2.2 Osteoporosis Drugs………………………………………………… 4-38
4.2.2.1 Bone-Building Drugs ………………………………… 4-39
4.2.2.2 Bisphosphonates……………………………………… 4-40
4.2.2.3 Receptor Activator of Nuclear Factor
KappaB Ligand Inhibitors ………………………….. 4-40
4.2.2.4 Salmon Calcitonin ……………………………………. 4-40
4.3 Competitive Analysis …………………………………………………………….. 4-41
Exhibit 4-1: 2013, Selected Pharmaceutical Treatments for Osteoporosis……… 4-11
Exhibit 4-2: 2013, Selected Emerging Pharmaceutical Treatments
for Osteoporosis …………………………………………………………………… 4-30
Exhibit 4-3: Estrogen/Hormone Therapy and Osteoporosis Drugs,
Market Forecast, 2012-2017 ………………………………………………….. 4-33
Exhibit 4-4: 2012, Estrogen/Hormone Therapy and Osteoporosis Drugs,
Sales by Product Category…………………………………………………….. 4-36
Exhibit 4-5: United States Patent Status of Selected Estrogen/
Hormone Therapy Drugs……………………………………………………….. 4-42
Exhibit 4-6: United States Patent Status of Selected Osteoporosis Drugs ……… 4-43
Exhibit 4-7: 2012, Estrogen/Hormone Therapy and Osteoporosis
Drugs Market, Share by Supplier ……………………………………………. 4-47
5. COMPANY PROFILES…………………………………………………………………….. 5-1
5.1 Alere, Inc. ……………………………………………………………………………… 5-1
5.2 The Cooper Companies, Inc…………………………………………………….. 5-1
5.3 GE Healthcare/General Electric Company …………………………………. 5-2
5.4 Hologic, Inc……………………………………………………………………………. 5-3
5.5 Eli Lilly and Company ……………………………………………………………… 5-5
5.6 Novartis AG …………………………………………………………………………… 5-7
5.7 Pfizer, Inc. …………………………………………………………………………….. 5-7
5.8 Roche Holding AG………………………………………………………………….. 5-9
Figure: Osteoporosis Management Products, Combined Market Forecast, 2012-2017
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!